NCT03648073View on ClinicalTrials.gov

[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

February 3, 2022

Study Completion Date

February 3, 2022

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

[68Ga]DOTATATE-PET/MRI

\[68Ga\]DOTATATE-PET/MRI

Trial Locations (1)

35294

University of Alabama at Birmingham Medical Center, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03648073 - [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter